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ABSTRACT
Introduction: Because of the advent of
monoclonal antibodies in the treatment of
metastatic melanoma, patients with this disease
are surviving longer. Early recognition of the
diseasehas thereforebecomeevenmore important.
Case report: We present a patient with
vitelliform maculopathy, a paraneoplastic
retinal maculopathy that is under-recognized.
Clinically the retinal findings of serous
detachments and pigmentary macular changes
are remarkable, while at the same time these
patients have surprisingly very few symptoms.
This is in contrast to patients who develop
melanoma associated retinopathy (MAR) who
are very symptomatic early in the disease, but
with more subtle retinal findings.
Conclusion: Monoclonal antibody treatment is
changing the survival rates in metastatic disease
making early diagnosis even more important.
Exudative polymorphous vitelliform
maculopathy (EPVM) needs to be recognized
early to avoid delay in diagnosis of metastatic
disease.




Due to the advent of monoclonal antibody
agents in the treatment of metastatic
melanoma, patients with this disease are
surviving longer [1]. Early recognition of the
disease has therefore become even more
important. We present a patient with
vitelliform maculopathy, a paraneoplastic
retinal maculopathy that is under-recognized.
Clinically the retinal findings of serous
detachments and macular pigmentary changes
are remarkable, while at the same time these
patients have surprisingly very few symptoms.
This is in contrast to patients who develop
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melanoma associated retinopathy (MAR) who
are very symptomatic early in the disease, but
with more subtle retinal findings.
Informed consent was obtained from all
patients for being included in the study.
CASE REPORT
A 65-year-old male being worked up for
metastatic disease was found to have multiple
exudative vitelliform lesions in both maculae
(Figs. 1, 3). These lesions are found in patients
with metastatic melanoma. Biopsy of an
occipital lesion confirmed melanoma (Fig. 5a).
A positron emission tomography (PET) scan also
showed lesions in the lung, axilla and
gallbladder (Fig. 5b). No choroidal masses were
found. Through radiology, the gallbladder was
felt to be the site of primary malignancy. The
metastatic lesions, as well as the exudative
macular lesions both improved with
monoclonal antibody (ipilimumab) treatment
(Figs. 2, 4). One year following treatment there
was no sign of recurrence of disease. The patient
has been followed up every 3 months since
using PET scans.
The patient initially had symptoms of
dizziness and the feeling that he was missing
characters to the left of fixation for seconds at
a time while reading. Following resection of
his R occipital mass, and treatment with
chemotherapy his symptoms slowly improved
over a 6-month period. He denied ever having
significant blurring, any types of photopsias, or
trouble with light/dark adaptation. His vision
was correctable to 20/25 in his right eye and
20/20 in his left eye. His color vision and pupils
were normal. Visual fields by confrontation
were normal while Humphrey Visual Field test
(HVF) 24-2 revealed a small central L
hemianopsia attributable to his occipital
Fig. 2 a Pigmentary and atrophic changes on OCT, and
b post-treatment resolution of serous detachment on OCT
in the right eye. OCT optical coherence tomography
Fig. 1 a Pigmentary and atrophic changes on OCT, b serous detachment on OCT in the pre-treatment right eye, and
c pigmentary and atrophic changes on color fundus photograph. OCT optical coherence tomography
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disease. His intraocular pressure was 13 mmHg
in both eyes. Slit lamp examination was
unremarkable. Funduscopic examination
revealed crisscross pigmentary changes in both
maculae with muting of the foveal reflex. Both
optic nerves and peripheral retinas were
normal. Motility examination was normal.
Heidelberg optical coherence tomography
(OCT) revealed multiple shallow retinal
pigment epithelial (RPE) detachments with
significant disruption of the outer retinal
layers with bright vitelliform lesions
throughout the areas of detachment (Figs. 1,
3). The areas of detachment on OCT responded
to treatment over a 4-month period without
recurrence (Figs. 2, 4).
The patient presented with significant retinal
RPE damage as seen in the fundus photographs
(Figs. 1c, 3c). Use of the OCT helped delineate
the numerous smaller shallow serous
detachments in each eye, which is not typical
of patients with Best’s Disease or central serous
retinopathy (CSR). Patients with CSR and Best’s
Disease typically have one central larger area of
detachment making them more acutely
symptomatic. In Best’s disease there is usually
also lipofuscin accumulation centrally causing
the ‘‘egg yolk’’ appearance. The crisscross and
linear pattern RPE changes seen in our patient
with EPVM are also atypical for Best’s disease
and CSR. The OCT helped monitor a response
to the patients’ systemic treatment without the
need of angiography. Fluorescein angiography
revealed the expected area of RPE damage with
minimal staining and no leakage (Figs. 6, 7).
Fundus autofluorescence imaging delineates the
linear yellowish lipofuscinoid deposits and
areas of old detachment, and small areas of
pigment epithelial atrophy (Fig. 8).
DISCUSSION
In the 1990s the 5-year survival rate of stage 4
melanoma to the brain was less than 4%,
until the advent of new therapies including
Fig. 3 a Pigmentary and atrophic changes on OCT, b serous detachment on OCT on pre-treatment left eye, and
c pigmentary and atrophic changes on Fundus photograph. OCT optical coherence tomography
Fig. 4 a Pigmentary and atrophic changes on OCT, and
b post-treatment resolution of serous detachment on OCT
in the left eye. OCT optical coherence tomography
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Fig. 6 Left eye ﬂuorescein angiogram
Fig. 5 a MRI brain showing RT metastatic melanoma, and b MRI abdomen showing mass in gall bladder (red line). MRI
magnetic resonance imaging
Fig. 7 Right eye ﬂuorescein angiogram
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monoclonal antibody treatment such as
ipilimumab revolutionized treatment
strategies. Now patients are surviving longer,
especially if diagnosed early [4]. Studies have
shown an improved 1-year survival of 39.3%
and 2-year survival rate of 24.2% [5].
Recognition of retinal findings associated
with melanoma is important, especially in
patients who have few symptoms such as in
the patient discussed here. EPVM is
pathognomonic of metastatic cancers,
including melanoma. Early recognition leads
to quicker identification of a primary site and
appropriate expedited treatment of the disease.
Unfortunately, information about eye
conditions associated with metastatic
melanoma patients still relies on the
collection of scattered case reports [2, 3].
The retinopathy of EPVM is a paraneoplastic
process, as seen in MAR, but without vascular
narrowing or optic atrophy. The lesions are
primarily in the maculae, and can have a
similar look to the vitelliform changes seen in
Best’s Disease [6], in which patients have a
vitelliform ‘‘yolk-like’’ lesion associated with a
serous detachment in the macula [7, 8]. The
material of the ‘‘egg yolk’’ in Best’s disease is
believed to be lipofuscin, and is often a
centralized mass within the area of
detachment, while in EPVM it usually appears
as small bright droplets layered in the deep
retinal layers, and show bright on OCT.
Patients with CSR [9] also have serous
detachments, but without any ‘‘egg yolk’’
accumulation or discoloration; the serous
detachment is secondary to choroidal vascular
hyperpermeability [10–12]. In contrast to
EPVM, there is also usually only one
symptomatic large serous detachment
centered on the macula without significant
pigmentary changes, and only one eye is
typically affected at a time. OCT is very
useful in differentiating these three conditions.
Testing by OCT is quicker and easier for these
patients, who are suddenly encompassed in care,
compared to previous testing with fluorescein
angiogram which required an injection. When
fluorescein angiography is performed in patients
with EPVM, it demonstrates some mild staining
of the lesions with no leakage typically. In Best’s
Disease and CSR obvious hyperfluorescence
and leakage is typically noted.
Fig. 8 Fundus autoﬂuorescence depicting areas of hyperautoﬂuorescence corresponding to areas of disease and detachment
in both eyes
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In MAR where symptoms of flickering,
shimmering and photopsias occur [13–16],
patients with EPVM often do not present with
these symptoms or any reduction of vision [17,
18]. The patient reported here did not complain
of such symptoms, or of any blurring of vision.
In one study only 2 out of 9 patients with
cutaneous melanoma had experienced
symptoms of shimmering [17]. In another
study [11], two patients, both with metastatic
cutaneous melanoma experienced no
symptoms of shimmering in their vision. ERG
had not been found to be useful in these
patients as it is usually non-diagnostic or
normal. This is not surprising since these
patients rarely complain of light adaptation
symptoms or nyctalopia. For this reason our
patient did not undergo ERG testing.
Serum antibody analysis can be difficult to
interpret in cases of paraneoplasia, but positive
findings with any of a series of recognized
retinal antigens can prompt further inquiry,
even if no primary malignancy is found.
Interestingly, our patient reacted with a 45 kd
retinal antigen that has been previously
reported in cases of macular degeneration and
CAR, and is suspected to be an example of
pigment epithelium derived factor
hypersensitivity [19]. Past literature reports
have identified a collection of different ocular
proteins involved in the paraneoplasia
exhibiting a range of different molecular
weights including those of 20, 22 [20], 23 [20],
40, 45, 47, 62, 120 and 145 kDa [17–21].
CONCLUSION
Monoclonal antibody treatment is changing
survival rates in metastatic disease making
early diagnosis even more important. PEVM
needs to be recognized early to avoid delay in
diagnosis of metastatic disease.
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